Dr. Nithin Reddy is a distinguished dermatologist specializing in medical, cosmetic, and surgical dermatology, with a particular focus on the use of laser technology and treatment of autoimmune connective tissue disorders. He graduated AOA (with honors) from Tufts University School of Medicine and completed his dermatology residency at Albert Einstein College of Medicine, where he served as Academic Chief Resident in his final year.

Dr. Reddy is a recognized authority in the fields of laser technology, autoimmune connective tissue disorders, and dermatologic surgery. He has authored multiple peer-reviewed articles, including significant publications on the efficacy of Lenabasum in dermatomyositis and the utility of Optical Coherence Tomography for diagnosing basal cell carcinoma. His research on IL-31 as a marker of pruritus in dermatomyositis was presented at the American College of Rheumatology annual meeting and has been influential in advancing dermatological care.

Professional Associations

• American Academy of Dermatology (AAD)

Innovation & Research Dr. Nithin Reddy has made significant contributions to the field of dermatology. His work primarily focuses on autoimmune connective tissue disorders and the application of laser technology in dermatology. Dr. Reddy's research has been instrumental in advancing the understanding and treatment of conditions like dermatomyositis, where he evaluated the role of Lenabasum, a cannabinoid receptor agonist, in reducing inflammation and pruritus. Additionally, his studies on the use of Optical Coherence Tomography for diagnosing basal cell carcinoma have provided valuable insights into non-invasive diagnostic techniques.

Selected Publications

• Duetsch A, Reddy ND, McLellan B, Shinoda K. Single-Cell Characterization of Lipomas and Identification of their Adipogenic Progenitors: A Transcriptomic Assessment. J Invest Dermatol; 2022.
• White B,...Reddy ND,...Werth VO. Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin Disease. A Randomized Clinical Trial. J Invest Dermatol 2022.
• Chen K, Zeidi M, Reddy ND, White B, Werth VP. Lenabasum, a cannabinoid type 2 receptor agonist, reduced CD4 cell population and downregulates type 1 and 2 interferon activities in lesional dermatomyositis skin. Annals of the Rheumatic Diseases; 2019.
• Maddukuri S,...Reddy ND,...Werth VP. Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum TM. Arthritis Res Ther. 2022.
• Reddy ND, Nguyen BT. The utility of Optical Coherence Tomography for diagnosis of basal Cell Carcinoma: A quantitative review. Br J Dermatol. 2019;180(3):475-483.
• Gonzalez JL, Reddy ND, Cunningham K, Nguyen BT. Multiple Cutaneous Squamous Cell Carcinoma in Immunosuppressed vs. Immunocompetent Patients. JAMA Dermatol. 2019. Doi: 10.1001/jamadermatol.2018.5595.
• Pancheri FQ, Peattie RA, Reddy ND, Ahamed T, Lin W, Ouellette TD, et al. Histology and Biaxial Mechanical Behavior of Abdominal Aortic Aneurysm Tissue Samples. J Biomech Eng. 2017;139(3).